| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8734847 | GENUS | Formulation of indomethacin |
Apr, 2030
(6 years from now) | |
| US8992982 | GENUS | Formulation of indomethacin |
Apr, 2030
(6 years from now) | |
| US9089471 | GENUS | Formulation of indomethacin |
Apr, 2030
(6 years from now) | |
Tivorbex is owned by Genus.
Tivorbex contains Indomethacin.
Tivorbex has a total of 3 drug patents out of which 0 drug patents have expired.
Tivorbex was authorised for market use on 24 February, 2014.
Tivorbex is available in capsule;oral dosage forms.
Tivorbex can be used as treatment of pain.
The generics of Tivorbex are possible to be released after 23 April, 2030.
Drugs and Companies using INDOMETHACIN ingredient
Market Authorisation Date: 24 February, 2014
Treatment: Treatment of pain
Dosage: CAPSULE;ORAL
More Information on Dosage
TIVORBEX family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic